ZMB Member Adalbert Krawczyk
ZMB Member
Adalbert Krawczyk
Next ZMB-Member
Prof. Dr. Adalbert Krawczyk
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 82512
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Immunology, Infectious Diseases and Transplantation
Research Overview
- Anti-HSV antibodies
- Nanoparticle based vaccines
- Anti-CMV antibodies
- Coronavirus SARS-CoV-2
- Antiviral Natural Products and Herbal Medicines
- Modification of exosomes for the development of new vaccines
Selected Publications
-
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19In: Nature Communications Vol. 12 (2021) Nr. 1, pp. 1813Online Full Text: dx.doi.org/ (Open Access)
-
Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe diseaseIn: Nature Communications Vol. 11 (2020) Nr. 1, pp. 1338Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide TherapyIn: Gastroenterology Vol. 158 (2020) Nr. 8, pp. 2180 - 2194Online Full Text: dx.doi.org/ (Open Access)
-
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8⁺ T Cells and Evolve at the Population LevelIn: Gastroenterology Vol. 156 (2019) Nr. 6, pp. 1820 - 1833Online Full Text: dx.doi.org/ (Open Access)
-
Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modelingIn: Journal of Hepatology Vol. 70 (2019) Nr. 1 Suppl., pp. e463Online Full Text: dx.doi.org/
-
Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of Hbeag Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2aIn: Hepatology Vol. 68 (2018) Nr. S1, pp. 234A - 235AOnline Full Text: dx.doi.org/
-
One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial : REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infectionIn: Journal of Hepatology Vol. 66 (2017) Nr. 1, pp. S96 - S97Online Full Text: dx.doi.org/
-
Update on safety and efficacy in the REP 401 protocol : REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infectionIn: Journal of Hepatology Vol. 66 (2017) Nr. 1, pp. S256 - S257Online Full Text: dx.doi.org/